The relationship between absence coronary artery calcification and myocardial perfusion single photon emission computed tomography

Ahmed Fathala

BACKGROUND: Coronary artery calcification score (CACS) is well validated prognostic tool in coronary artery disease (CAD). The data on the prevalence of myocardial ischemia on Myocardial Perfusion Single Photon Emission Computed Tomography (MPS) in symptomatic patients with zero CACS and low to intermediate risk probability is lacking and controversial. In general, the presence of coronary calcified plaques is associated with higher risk for CAD (8). However, there are some studies questioned the capability of MPS to exclude inducible ischemia at functional testing as myocardial perfusion single photon emission computed tomography. Positron Emission Tomography (PET) in patients at low or intermediate risk may be an alternative modality for the detection of coronary artery disease. However, patients with abnormal MPS will need further imaging with CCTA. Patients with normal MPS underwent additional imaging with CCTA.

RESULTS: All patients had zero CACS, 122 (78%) had normal MPS, and 35 (22%) had abnormal MPS. Abnormal MPS includes fixed defect 22 (13%), equivocal 10 (6%), and reversible defect 4 (3%). All patients with abnormal MPS had further imaging with CTCA. CTCA was normal in 30 (85%) patients, one patient had coronary artery stenosis more than 50%, one patient had coronary artery stenosis less than 50%, one patient had normal MPS and normal coronary artery and 2 patients had myocardial bridging. Patients with abnormal MPS and normal coronary artery had dilated anomalous origin coronary artery, and 2 patients had myocardial bridging. Patients with normal MPS and normal coronary artery had dilated cardiomyopathy 14 (40%), asymmetrical septal hypertrophy 1 (3%), and mitral valve disease 3 (9%).

CONCLUSION: Zero CACS in stable patients with low or intermediate risk indicates very low likelihood of obstructive CAD, less than 1%. Patients with Zero CACS and normal MPS most likely will not benefit from further testing however, patients with abnormal MPS will need further imaging with CCTA. CCTA is helpful in this group of patients for evaluation of coronary artery and cardiac morphology.

Key Words: Coronary; Artery; Disease; Heart; Ventricular; Cardiomyopathy

MPS acquisition and analysis

 Patients underwent rest-stress myocardial perfusion studies with either a separated-day protocol or a same-day protocol. The choice of tracer and same-day or separated-day protocol was based on logistic requirements. The rest dose in patients who underwent a separated-day rest-stress protocol was 1100 Megabecqurel (MBq) of either technetium-99m tetrofosmin or tetrofosmin. The stress dose in patients who underwent the rest-stress same-day protocol was 1100 MBq MCI of either Tc-99m sestamibi or tetrofosmin. Tc-99m sestamibi or Tc-99m Tetrofosmin was injected during peak pharmacological vasodilatation with adenosine (140μg/kg/min), or dipyridamole. Single photon computed tomography (SPECT) imaging was started 30 minutes following pharmacological vasodilatation. Rest SPECT myocardial perfusion imaging was initiated at approximately 60 minutes following injection. SPECT imaging was performed with line source attenuation correction at 900 dual-detector gamma cameras (Cardio MD, Philips Medical System, Milpitas, California) equipped with attenuation correction and truncation compensation. The acquisition parameters and post processing were performed according to the most recent guidelines of the ASNC for nuclear cardiology procedures (14).

All images were reoriented in short, vertical, and horizontal views utilizing Auto SPECT (Cedars-Sinai Medical Center, Los Angeles, California) for proper cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com

Clin Cardiol J Vol 1 No 1 December 2017
visual interpretation by an experienced nuclear medicine physician. The reader was not biased by clinical information. Stress and rest perfusion images were scored using 17 tomographic segments, which included 6 segments each for the basal and midventricular slices, and 4 segments for the apical short-axis slices. The final segment is located on the most apical part of the left ventricle. Finally, gated short-axis images were processed with quantitative SPECT software to measure the ejection fraction. In the visual analysis the 17 segments were scored for perfusion defects on a 4-point system (0 = normal; 1 = mild; 2 = moderate; and 3 = severe) for both the stress and rest images. From this analysis, ischemia was defined as a change in segmental score between stress and rest. Segments with no change between stress and rest were classified as nonreversible. Summed stress and rest scores were calculated by summing the 17 segmental scores in each imaged set. Utilizing the summed difference score (SDS) in measuring defect reversibility was calculated from the difference between the summed stress and rest scores. A SDS lower than 2 was considered nonischemic, 2 to 7 was considered as mild ischemia, and greater than 7 as considered as moderate to severe ischemia. The reader made the final determination of an abnormal SPECT study by comparing both the perfusion and functional data. The perfusion defects represented by the perfusion scores at stress and rest were used to form the interpretation of the MPS studies. A gated SPECT result was considered normal if as follows: no visual perfusion defect, summed stress score <3, a left ventricular ejection fraction (LVEF) at rest >50%.

Coronary artery calcium score acquisition and analysis

All patients with heart rates >70 bpm received oral β-blocker therapy, with 50 or 100 mg of metoprolol tartrate (AstraZenea, Zoetermeer, the Netherlands) after stress testing to achieve a heart rate <70 bpm for the CAC scan. A nonenhanced CT scan (High Definition CT XT; GE Healthcare) during breath-hold at end expiration to calculate the total CAC score was acquired with ECG triggering at 75% of the R-R interval and with the following scanning parameters: 40 or 48 sections and 2.5-mm section thickness; gantry rotation time, 130 ms; tube voltage, 120 kV; and a tube current of 125 mA. If patients were not able to hold their breath, a free breathing CT was acquired. Postprocessing was conducted at a dedicated workstation using Smartscore software (GE Healthcare). The CAC score was calculated using the standard Agatston criteria (5).

Coronary CT angiography acquisition

Patients without contraindications received metoprolol targeting a heart rate of ≤ 65 bpm and nitroglycerin 0.8 mg sublingually before image acquisition. A bolus tracking technique was used to calculate the time interval between intravenous contrast (Visipaque 320, GE Healthcare; Milwaukee, Wisconsin, USA) infusion and image acquisition. Final images were acquired with a triphasic protocol (100% contrast, 40%/60% contrast/saline, and 40 cc saline). The contrast volume and infusion rate (5 to 6 cc/s) were individualized according to scan time and patient body habitus. Retrospective ECG-gated data sets were acquired with the GE high definition CT (GE Healthcare; Milwaukee, Wisconsin, USA) with 64 × 0.625 mm slice collimation and a gantry rotation of 350 msec (mA=300 to 800; kV=120). Pitch (0.16 to 0.24) was individualized to the patient’s heart rate. The CCCTA data sets were reconstructed with an increment of 0.4 mm using the cardiac phase with the least cardiac motion.

Coronary CT angiography image analysis

Images were processed using the GE Advantage Volume Share Workstation (GE Healthcare, Milwaukee, Wisconsin, USA) and visually interpreted by 2 expert observers blinded to all clinical data. A 17-segment model of the coronary arteries and 4-point grading score (normal, mild [50% to 69%], severe [70%]) was used for the evaluation of coronary stenosis, obstructive CAD was defined as coronary diameter stenosis ≥ 50% (15).

Statistical analysis

Data were entered into SPSS V 20.0 for analysis (SPSS, Chicago, Illinois). All continuous variables were expressed as mean ± SD. Relationship between categorical variables was assessed using chi-square test. Comparison between group mean was performed using two independent sample t-test. A p-value of less than 0.05 indicated statistically significant difference.

RESULTS

Our sample consisted of 157 patients, (mean age 53 years +/- 10; 88 (56%) female patients, 69 (44%) male patients who were suspected to have CAD and having low to intermediate pretest likelihood for CAD according to Diamond and Forrester criteria (Table 1). All patients had zero CACS. 122 (78%) patients had normal MPS, and 35 (22%) had abnormal MPS, abnormal MPS includes fixed defect 22 (13%), equivocal 10 (6%), and reversible defect 4 (3%) (Table 2). All patients with abnormal MPS had further imaging with CTCA, CTCA was normal in 30 (85%) patients, one patient had coronary artery stenosis more than 50%, one patient had coronary artery stenosis less than 50%, one patient had anomalous origin coronary artery, and 2 patients had myocardial bridging (Table 3). There were several findings in patients with abnormal MPS and normal coronary artery such as Dilated Cardiomyopathy 14 (40%) (Figures 1 and 2) shows asymmetrical septal hypotrophy, 1 (3%), and mitral valve disease 3 (9%). There was no association with conventional CAD risk factors with MPS results (Table 4).
The negative predictive value of Zero CACS versus exercise testing and myocardial perfusion imaging

Dedic et al. in a study consistent of 791 consecutive stable patients showed that patients with stable chest pain who underwent CAC scoring and Exercise Electrocardiogram, a Zero CAC score had substantially lower likelihood ratio compared to and Exercise Electrocardiogram; 0.11, 0.13, 0.13 vs. 0.93, 0.55, 0.46 in the low, intermediate, and high-risk group. In low risk patients (0-30%) a negative CAC reduced the likelihood of obstructive CAD to 5% obviating the need for further diagnostic workup in substantial proportion of patients. For intermediate risk patients (30% to 70%) the likelihood decreased to 5% to 25%, but in high risk group Zero CAC score cannot exclude obstructive CAD (22). The negative predictive value of Zero CACS score for detection of myocardial ischemia was investigated by Esteves et al., 1999 patients out of 206 had zero CACS, and of those 99 patients only one patient had myocardial ischemia on myocardial perfusion PET. Also CACS of zero was the strongest independent factors of normal myocardial perfusion PET (8). Despite this high negative predictive value of zero CACS for prediction of myocardial ischemia, we strongly believe, further testing with MPS or CCTA is necessary in patients with zero CACS presented to the emergency department, patients with higher pretest probability, and young patients with high suspicious of coronary artery anomalies. CCTA is particularly helpful in patients with high suspicious of false positive MPS such as patients with DCMP, HCMP, Left bundle branch block, coronary artery anomalous, and patients with known structural or congenital heart disease.

STUDY LIMITATIONS

One of our study limitations is that our gold standard for evaluating CAD was CCTA instead of invasive coronary angiography, which is the gold standard method of detection of CAD. However, many studies have shown that CCTA has 90-94% sensitivity and 96-100% negative predictive value (23). Our patients with normal MPS did not undergo any further imaging, potentially false negative results could not be completely excluded due to many reasons such as balanced ischemia and or left main coronary artery disease, also These group of patients with normal SPECT may have noncalcified plaque or non-obstructive CAD.

CONCLUSION

In conclusion zero CACS in stable patients with low or intermediate risk indicate very low likelihood of obstructive CAD, less than 1% and normal MPS most likely will not benefited from further testing. However, patients with abnormal MPS will need further imaging with CCTA. CCTA is

**TABLE 2**

**MPS results, N=157**

<table>
<thead>
<tr>
<th></th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal MPS</td>
<td>122</td>
<td>78%</td>
</tr>
<tr>
<td>Abnormal MPS</td>
<td>35</td>
<td>22%</td>
</tr>
<tr>
<td>Fixed Defect</td>
<td>21</td>
<td>13%</td>
</tr>
<tr>
<td>Equivocal</td>
<td>10</td>
<td>6%</td>
</tr>
<tr>
<td>Reversible Defect</td>
<td>4</td>
<td>3%</td>
</tr>
</tbody>
</table>

**TABLE 3**

**CT coronary angiography results, N=35**

<table>
<thead>
<tr>
<th>Coronary Artery</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Coronary Artery</td>
<td>30</td>
<td>85%</td>
</tr>
<tr>
<td>Coronary artery stenosis, more than 50%</td>
<td>1</td>
<td>3%</td>
</tr>
<tr>
<td>Coronary artery stenosis, less than 50%</td>
<td>1</td>
<td>3%</td>
</tr>
<tr>
<td>Anomalous coronary artery origin</td>
<td>1</td>
<td>3%</td>
</tr>
<tr>
<td>Myocardial bridging</td>
<td>2</td>
<td>6%</td>
</tr>
</tbody>
</table>

**TABLE 4**

**CT coronary angiography and Cardiac Morphology findings in patients with abnormal MPS, N=35**

<table>
<thead>
<tr>
<th>Coronary Artery</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Coronary and normal Cardiac Morphology</td>
<td>13</td>
<td>37%</td>
</tr>
<tr>
<td>Abnormal CT coronary angiography and/or abnormal Cardiac Morphology</td>
<td>22</td>
<td>63%</td>
</tr>
<tr>
<td>Dilated Cardiomyopathy</td>
<td>14</td>
<td>40%</td>
</tr>
<tr>
<td>Coronary artery stenosis, more than 50%</td>
<td>1</td>
<td>3%</td>
</tr>
<tr>
<td>Asymptomatic septal hypertrophy</td>
<td>1</td>
<td>3%</td>
</tr>
<tr>
<td>Myocardial bridging</td>
<td>2</td>
<td>6%</td>
</tr>
<tr>
<td>Anomalous coronary artery origin</td>
<td>1</td>
<td>3%</td>
</tr>
<tr>
<td>Mitral valve disease (stenosis, post mitral valve replacement)</td>
<td>3</td>
<td>9%</td>
</tr>
</tbody>
</table>

**DISCUSSION**

Our data showed that a CAC score of zero has less than 1% (0.6%) low limiting CAD based on CCTA in symptomatic stable patients with low to intermediate probability of CAD. It appears that CAC score in this group of patients is appropriate, safe, and cost effective as initial diagnostic test for CAD. However, the prevalence of abnormal MPS in patients with CAC score of zero is relatively high up to 22%. Most patients with abnormal MPS do not have obstructive CAD, based in our data, one patient out of 35 patients with abnormal MPS had obstructive CAD based on CCTA, importantly, CCTA showed other findings that potentially explaining the abnormal perfusion on myocardial imaging such as dilated and hypertrophic cardiomyopathy, mitral valve disease, and myocardial bridging, this finding is extremely important, indicating that not all abnormal myocardial perfusion in absence of obstructive CAD based on conventional coronary angiography is false positive.

According to our data, it is appropriate to initiate the cardiac work-up for patients with low to intermediate risk with CAC score due to its relative low cost, low radiation, and wide availability. Further functional imaging with MPS is indicated to exclude myocardial ischemia. In patients with zero CACS score and normal MPS no further work up is indicated, however, with abnormal MPS additional imaging with CCTA may be indicated.

Prevalence of obstructive CAD among patients with a Zero CACS score

The prevalence of obstructive CAD in patients with zero CACS is variable from less than 1% to about 3% based strongly on population studied, patient’s presentation, and pretest probability of CAD. In asymptomatic patients with a zero CACS score, the prevalence of obstructive CAD is lower than 1% (16), however, in symptomatic patients a zero CACS score is associated with a low likelihood of, up to 3%. In a systematic review by sarawat et al. it has been shown that absence of CAC was associated with a very low risk of future cardiovascular events, with a modest incremental value of other diagnostic test in this this very low-risk group (17). In another major study by villene et al, 10,037 symptomatic patients without CAD who underwent CCTA and CAC scoring, 84% had no CAD, 13% had no obstructive CAD, and 3.5% had more than 50% stenosis. It was concluded that in symptomatic patients with a zero CACS score, obstructive CAD is possible and is associated with increased cardiovascular events, and CAC score did not add incremental prognostic information to CCTA (17).

Relationship between Zero CACS score and myocardial perfusion

In our study, 35 (22%) patients out 157 patients with zero CACS score had abnormal myocardial perfusion (abnormal MPS), the pattern of perfusion abnormalities included fixed defect 21 (13%), equivocal myocardial perfusion (10) (6%), and reversible defect 4 (3%), but obstructive CAD was identified in one patient only based on CCTA. Interestingly, there were many cardiac morphological abnormalities on CCTA that could potentially explain the abnormal myocardial perfusion in absence of obstructive CAD. For example, CCTA showed one anomalous origin right coronary artery form left coronary ostia, two myocardial bridging, and one patient with non-obstructive CAD (less than 50 luminal stenosis); all these patients had zero CACS score, abnormal myocardial perfusion, and patent coronary arteries. This finding could explain patient’s symptoms and abnormal myocardial perfusion and not necessarily indicate false positive MPS. In addition, there were several cardiac morphological abnormalities on CCTA, such as dilated Cardiomyopathy (DCMP), hypertrophic cardiomyopathy (HCM), and mitral valve disease. Previous study showed that, SPECT perfusion abnormalities in patients with normal coronary artery on CCTA is 12% (18) which is relatively less than our population. We strongly believed these important findings and may explain why in many previous studies that MPS had low specificity when compared to gold standard conventional coronary angiography. For example, in our patients, there were 14 patients out of 35 had DCMP, one patients had HCM, and two patients had mitral valve disease. There are several possible reasons for the presence of perfusion defect in DCMP. The presence of myocardial fibrosis and scarring could account for fixed perfusion defect (19), in addition, dilatation of left ventricle and abnormal cell membrane could cause variable tracer uptake and distribution, it is also known that stress induce left ventricle geometry change may cause reversible perfusion defects in DCMP, exercise induced coronary spasm, mitral valve prolapse, aortic valve stenosis had been associated with myocardial perfusion abnormalities (20). In hypertrophic cardiomyopathy, there is thickening of the myocardium, practically the septum, this can result in significant increased activity in the septum, which result in the significant decreased uptake in the other myocardial walls creating perfusion abnormalities (21).
particular helpful in this group of patients for not only evaluation of coronary artery disease but also for cardiac morphological evaluation.

REFERENCES


